trending Market Intelligence /marketintelligence/en/news-insights/trending/bxdJXzy4A2Iecv1WRTyZhQ2 content esgSubNav
In This List

Emergent buys Sanofi's smallpox vaccine biz

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Emergent buys Sanofi's smallpox vaccine biz

Emergent BioSolutions Inc. completed the acquisition of Sanofi SA's smallpox vaccine ACAM2000, including two manufacturing facilities: one in Canton, Mass., and another in Rockville, Md.

The Maryland-based company paid $117.5 million in upfront cash and will pay a further $7.5 million once certain conditions are met.

Emergent will also assume responsibility for an existing 10-year contract valued at up to $425 million with the Centers for Disease Control and Prevention.

The contract has a remaining value of about $160 million for deliveries of ACAM2000 to the Strategic National Stockpile.